Brii Bio
is a North Carolina-based biotechnology company that develops and commercializes antibody-derived therapies for the treatment of infectious diseases... Read moreBrii Bio
is a North Carolina-based biotechnology company that develops and commercializes antibody-derived therapies for the treatment of infectious diseases... Read more
2018
PublicHong Kong Stock Exchange02137.HK
News
Mar 30, 2025
Benzinga
Brii Bio: Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Mar 21, 2025
Marketscreener
Brii Bio: Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2024
Jan 02, 2025
Pharmaceutical Business Review
Brii Bio: Brii Biosciences acquires BRII-179 assets from VBI Vaccines
Jan 02, 2025
The Business Journals: Raleigh/Durham
Brii Bio: Durham firm acquires hepatitis B drug from defunct company
Nov 19, 2024
PR Newswire
Press Release: Brii Bio : Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFN Combination versus PEG-IFN Alone at AASLD's The Liver Meeting 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
Aug 19, 2024
Marketscreener
Brii Bio: Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2024
Jun 07, 2024
MarketScreener
Brii Bio: Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL Congress 2024
May 13, 2024
MarketScreener
Brii Bio: Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
Mar 22, 2024
Marketscreener
Brii Bio: Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Feb 17, 2024
Biospectrum Asia
Brii Bio: US-based VBI Vaccines sells manufacturing capabilities to China's Brii Biosciences for $33 M
Brii Bio Competitors
1
2
3
4
5
6
7
8
9
10